About Ascendo Biotechnology

Introduction

Ascendo Biotechnology is a clinical-stage biopharmaceutical company focused on developing first-in-class immunotherapies by targeting novel innate immune checkpoints. Leveraging advances in dysregulated immune biology, the company is building a pipeline to address significant unmet needs in oncology and autoimmune diseases.

Its lead program, ASD141, is a first-in-class monoclonal antibody targeting the platelet-derived checkpoint TLT-1 to remodel the tumor microenvironment. Preclinical studies demonstrated robust anti-tumor activity as both a monotherapy and in combination with checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4. ASD141 is currently in Phase I clinical development.

Ascendo’s second program, ASD001, targets the TLT-1/Mac-1 axis to modulate innate immune responses in autoimmune diseases, with a focus on indications such as inflammatory bowel disease and systemic lupus erythematosus. ASD001 is currently in preclinical development.

Founded in 2019 as a spin-out from BRIM Biotechnology, Ascendo has established a growing intellectual property portfolio and continues to advance both internal and in-licensed programs. The company is actively seeking strategic partnerships to accelerate development and maximize global impact.